169 related articles for article (PubMed ID: 25602514)
21. Functional role of endothelial CXCL16/CXCR6-platelet-leucocyte axis in angiotensin II-associated metabolic disorders.
Collado A; Marques P; Escudero P; Rius C; Domingo E; Martinez-Hervás S; Real JT; Ascaso JF; Piqueras L; Sanz MJ
Cardiovasc Res; 2018 Nov; 114(13):1764-1775. PubMed ID: 29800106
[TBL] [Abstract][Full Text] [Related]
22. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
23. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
[TBL] [Abstract][Full Text] [Related]
24. Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.
Zhu J; Ning RB; Lin XY; Chai DJ; Xu CS; Xie H; Zeng JZ; Lin JX
Am J Hypertens; 2014 Aug; 27(8):1112-24. PubMed ID: 24603314
[TBL] [Abstract][Full Text] [Related]
25. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.
Tsai SH; Huang PH; Peng YJ; Chang WC; Tsai HY; Leu HB; Chen JW; Lin SJ
Cardiovasc Res; 2013 Dec; 100(3):501-10. PubMed ID: 24225494
[TBL] [Abstract][Full Text] [Related]
26. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
27. Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke.
Certo M; Endo Y; Ohta K; Sakurada S; Bagetta G; Amantea D
Pharmacol Res; 2015 Dec; 102():298-307. PubMed ID: 26546745
[TBL] [Abstract][Full Text] [Related]
28. Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease.
Marchesi C; Rehman A; Rautureau Y; Kasal DA; Briet M; Leibowitz A; Simeone SM; Ebrahimian T; Neves MF; Offermanns S; Gonzalez FJ; Paradis P; Schiffrin EL
Cardiovasc Res; 2013 Mar; 97(3):562-70. PubMed ID: 23250918
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
[TBL] [Abstract][Full Text] [Related]
30. Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion.
Hong N; Ye Z; Lin Y; Liu W; Xu N; Wang Y
Aging (Albany NY); 2021 Jul; 13(14):18515-18526. PubMed ID: 34292876
[TBL] [Abstract][Full Text] [Related]
31. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Cesario RM; Stone J; Yen WC; Bissonnette RP; Lamph WW
Cancer Lett; 2006 Aug; 240(2):225-33. PubMed ID: 16271436
[TBL] [Abstract][Full Text] [Related]
32. Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo.
Alvarez A; Piqueras L; Blazquez MA; Sanz MJ
Br J Pharmacol; 2001 Jun; 133(4):485-94. PubMed ID: 11399665
[TBL] [Abstract][Full Text] [Related]
33. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF.
Yamagishi S; Nakamura K; Ueda S; Kato S; Imaizumi T
Cell Tissue Res; 2005 Jun; 320(3):437-45. PubMed ID: 15846509
[TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
[TBL] [Abstract][Full Text] [Related]
35. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
36. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation.
da Cunha V; Tham DM; Martin-McNulty B; Deng G; Ho JJ; Wilson DW; Rutledge JC; Vergona R; Sullivan ME; Wang YX
Atherosclerosis; 2005 Jan; 178(1):9-17. PubMed ID: 15585195
[TBL] [Abstract][Full Text] [Related]
37. Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanism.
Takata H; Yamada H; Kawahito H; Kishida S; Irie D; Kato T; Wakana N; Miyagawa S; Fukui K; Matsubara H
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):311-20. PubMed ID: 23736171
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling.
Ohshima K; Mogi M; Nakaoka H; Jing F; Iwanami J; Min LJ; Tsukuda K; Kanno H; Ogimoto A; Higaki J; Horiuchi M
J Am Soc Hypertens; 2012; 6(6):375-84. PubMed ID: 23107893
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice.
Schroeter MR; Humboldt T; Schäfer K; Konstantinides S
Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
